Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis Abstract Purpose: Predicting prognosis and treatment outcomes for patients with for nasopharyngeal carcinoma (NPC) has been difficult due to the heterogeneous nature of the disease This study aimed to evaluate pretreatment copy number of plasma Epstein-Barr virus (EBV) DNA as an outcome marker for survival in NPC.
Nasopharyngeal carcinoma (NPC) has a significantly skewed geographic incidence; it is more prevalent in Southeast Asian countries and in certain populations of the Arctic region (Inuits and Aleuts), the Middle East and Northern Africa [1] . NPC occurs sporadically (<1/100,000) in other regions and populations of the world [2] . NPC is endemic in southern China and Sarawak, Malaysia with an incidence of >20/100,000 population [1, [3] [4] [5] [6] . Radiotherapy, plus different chemotherapy regimens, are the standard therapy for treating NPC [7] . Most patients (75-90%) present with locoregionally advanced disease; often with lymph node metastasis [2] . Patients with locoregional advanced NPC have poor prognoses and distant metastasis is the main cause of treatment failure [8] . Patients with distant metastasis (stage IV disease) have a five-year survival rate of <10% [2] . Another serious problem is the development of long term sequelae due to treatment with radiation and chemotherapy, including radiation-induced malignant tumors [2] .
The etiology of NPC is not well understood and involves multiple components, including genetic, epigenetic, and environmental factors [1, 9, 10] . Infection by EBV can progress from a lytic to latent phase in nasal epithelial cells that have already achieved a premalignant state, as evidenced by mis-regulated expression of cell cycle proteins. Most cases of NPC are thought to result from clonal expansion of these cells prior to later events of transformation. Once a latent infection is established, viral proteins including Epstein-Barr nuclear antigen 1 (EBNA1), latent membrane protein 1 (LMP1), and LMP2 and viral micro RNAs alter the patterns of gene and protein expression in both nasopharyngeal cells and the neighboring stroma. The result is increased potential for proliferation, invasion and angiogenesis, decreased apoptotic potential and heightened immune activation. These extensive changes within the tumor niche promote the transformation to a malignant state.
Predicting the prognosis and treatment outcomes for patients with NPC has been difficult, likely due to the heterogeneous nature of the disease [1] . Although the TNM staging system is used as a prognostic indicator for NPC, a there is still a wide range treatment outcomes in patients with similarly staged tumors [11] . Various studies have evaluated potential molecular biomarkers to predict NPC progression. The quantification of the levels of Epstein-Barr virus (EBV) DNA prior to initiation of treatment has shown promise as a clinical tool for diagnosing NPC and for evaluating risk stratification, monitoring and prognosis [12] [13] [14] [15] [16] . EBV DNA levels correlate positively with disease stage and prognosis in NPC [16] . In addition, several groups have shown that plasma EBV DNA load is significantly associated with tumor volume, measured by a treatment planning system, computed tomography (CT) or magnetic resonance imaging (MRI) [17] [18] [19] [20] . The clinical relevance of this association is supported by findings that DNA load is correlated with apoptosis of tumor cells [21] , and that viral DNA in circulation exists as fragments of free, non-encapsulated DNA [22] . Evaluation of EBV DNA levels is currently considered the strongest biomarker, which complements TNM classification in determining the prognosis of patients with NPC [23] . Quantification of EBV DNA levels using quantitative PCR (qPCR) shows good sensitivity and specificity at detecting NPC prior to therapy and may also be useful in diagnosing patients with early stage (stage I/II) NPC [24] [25] [26] .
Published data evaluating the use EBV DNA for predicting survival is mostly limited to studies with small patient populations. The objective of this study was to evaluate pre-treatment copy number of plasma EBV DNA as an outcome marker for survival in NPC.
Materials and Methods

Search strategy
The meta-analysis was performed in accordance with the PRISMA guidelines. MEDLINE, CENTRAL and Embase databases were searched until April 7, 2015 using the following search terms: (plasma Epstein-Barr virus DNA) AND (nasopharyngeal carcinoma), (Epstein Barr virus OR EBV) AND (nasopharyngeal carcinoma). Included studies were randomized controlled trials, two-arm prospective studies or retrospective studies in patients with newly diagnosed NPC. All included studies had to quantitatively report survival data. Reviews, letters, comments, editorials, case reports, proceedings and personal communications were excluded. Two reviewers determined the appropriateness of a study for inclusion and a third reviewer was consulted to resolve any discrepancies.
Data extraction and quality assessment
The following data was extracted: name of first author, study design, number of patients, gender, method of measuring EBV DNA, length of follow-up and cut-off of EBV DNA for a given outcome assessment.
The quality of the included studies was evaluated using the method of Hayden et al. [27] . This analysis assesses six sources of bias related to study participation, study attrition, prognostic factor measurement, confounding measurement and account, outcome measurement and analysis. The data Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported Note:Age was presented by mean or percentage for age groups if not specified. a Data were presented by median and range. b Data were presented by median and inter-quartile range c To determine the hazard ratio (HR), the cut-off point was ≥11333 copies/mL versus <326 copies/mL. d To determine the HR, the cut-off points were >5000 versus ≤5000. Abbreviations: PCR=polymerase chain reaction; qPCR=quantitative PCR; RT-PCR=real-time PCR.cating no one study overly; NR=Not reported were extracted and the quality of the included studies assessed by two independent reviewers and a third reviewer was consulted for resolution of disagreement.
Data analysis
The primary outcome was overall survival and the secondary outcomes were progression-free survival, relapse-free survival, disease-free survival and distant metastasis-free survival.
Hazard ratio (HR) and 95% confidence interval (95% CI) were used as the index of effect size; HR > 1 indicates higher risk for the occurrence of events (e.g., death, progression, relapse, distant metastasis, etc.) in patients with higher levels of EBV DNA. Heterogeneity among the studies was assessed by the Cochran Q and the I2 statistic. The Q statistic was defined as the weighted sum of the squared deviations of the estimates of all studies; P< 0.10 was considered statistically significant for heterogeneity. For the I2 statistic, which indicated the percentage of the observed between-study variability due to heterogeneity, the suggested ranges are as follows: no heterogeneity (I2 = 0-25%); moderate heterogeneity (I2 =25-50%); large heterogeneity (I2 = 50-75%); and, extreme heterogeneity (I2 = 75-100%). If either P< 0.1 for the Q statistics or the I2 statistic was >50%, a random-effect model was used (DerSimonian-Laird method); otherwise, a fixed-effect model (Mantel-Haenszel method) was used. A 2-sided P-value < 0.05 was considered statistically significant. The leave-one-out approach was used to assess sensitivity of meta-analysis for overall survival. To evaluate whether EBV status may have affected the pooled results, a subgroup analysis was performed that included only those studies with EBV-positive patients comprising ≧ 90% of the total. Publication bias was assessed by constructing funnel plots for the primary outcome. The absence of publication bias was indicated by the data points forming a symmetric funnel-shaped distribution. Egger's test was performed to examine the symmetry of funnel plot; a one-tailed P > 0.05 indicated there was no publication bias. All statistical analyses were performed using the statistical software Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ, USA).
Results
Literature search
Of the 123 studies initially identified, 66 were excluded for being irrelevant (Figure 1 ). The remaining 57 were fully evaluated for inclusion and 41 were eliminated for not reporting the outcomes of interest, reporting data that could not be pooled for a meta-analysis, not being relevant or reporting findings from a study that was already included. Sixteen studies were included in the study with a total of 7698 patients [12, 13, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Three of the studies were retrospective in design and the remaining 13 studies were prospective (Table 1) . No randomized controlled studies were included. The sample size ranged 69 to 3113 patients, with two studies having >2000 patients. The mean or median age ranged from 45-49.77 years. Except for one study [40] , the majority of patients were male (72.6%-91.2%). The median follow-up duration ranged from 21 months to 6 years. The methods for measuring levels of EBV virus included quantitative PCR (qPCR), fluorescent qPCR and real-time (RT)-PCR. The cut-off points for EBV DNA varied across studies and ranged from 307-50,000 copies/mL. Ten studies reported the percentage of EBV-positive patients (70%-100%). Ten studies also reported data for the distribution of tumors among the three WHO types (I: keratinizing squamous cell carcinoma, II: differentiated non-keratinizing carcinoma, and III: undifferentiated carcinoma) with the proportion of patients with WHO Type I disease ranging from 0% to 7.5%). Eight studies reported data for clinical or disease stage; however, none of the studies reported the proportion of EBV-positive patients for each WHO tumor type or clinical stage.
Meta-analysis
Across the 13 studies that reported findings for overall survival, there was evidence of heterogeneity (Q = 31.3, P = 0.002, I 2 = 61.6%); therefore, a random-effects model was used to generate pooled estimate. The pooled HR was 3.005 (95% confidence interval [CI] = 2.245-4.022; P < 0.001), indicating that higher levels of EBV DNA were associated with higher risk of death (Figure 2 ). Sensitivity analysis using the leave-one-out approach found that the direction and magnitude of the combined estimates and the hazard ratios (HR) did not change when individual studies were removed one at a time (Figure 3 ), indicating no one study overly influenced the findings.
Results of meta-analysis for all survival outcomes are summarized in Table 2 . Six studies provided data pertaining to progression-free survival. A fixed-effect model was used as there was no sign of heterogeneity among the studies (Q = 3.4, P = 0.643, I 2 = 0%). The meta-analysis showed that the pooled HR was 2.420 (95% CI = 1.806-3.244, P < 0.001), indicating patients with high levels of pre-treatment EBV DNA had higher risk of disease progression compared with those with low levels of EBV DNA. Similarly, additional analyses indicated that high levels of EBV DNA prior to therapy were associated with a higher risk of disease relapse and recurrence of disease (HR = 2.202, 95% CI = 1.462-3.317, P < 0.001 for relapse-free survival; HR = 3.121, 95% CI = 2.273-4.285, P < 0.001 for disease-free survival). In addition, high pre-treatment EBV DNA levels were associated with higher risk of the occurrence of distant metastasis (HR = 3.684, 95% CI = 3.055-4.444, P < 0.001).
The results of a subgroup analysis showed that our pooled results for each outcome were not affected by the patients' EBV status. The direction and magnitude of the association in a subgroup of studies whose patient populations were at least 90% EBV-positive did not deviate from the pooled results of all included studies (Table 3) .
Publication bias and quality assessment
Analysis of publication bias found there was no evidence by Egger's test for publication bias (P = 0.109) (Figure 4 ). Quality assessment found that for most of the included studies there was low risk of bias for study participation, study attrition, measurement of prognostic factors, outcome measurements, confounding measurements and accounts, and analysis (Table  4) , indicating the studies were generally of moderate to high quality.
Discussion
Sixteen studies were included in the meta-analysis with a total of 7698 patients. For overall survival, the pooled HR was 3.005 (95% CI = 2.245-4.022; P < 0.001), indicating that higher levels of EBV DNA prior to therapy were associated with higher risk of death. The pooled estimates also indicated that higher levels of pre-treatment EBV DNA was associated with an increased risk of relapse and disease recurrence, disease progression, and distant metastasis than low levels of pre-treatment EBV DNA (P values < 0.001). The meta-analysis found that high pre-treatment levels of EBV DNA had good value as a prognostic indicator of survival and disease outcomes in patients with NPC. Most of the studies included in this meta-analysis found that increased levels of EBV DNA prior to treatment was associated with poor overall survival [13, [28] [29] [30] [32] [33] [34] [35] [36] [37] 39, 40] . Of the studies that evaluated the other outcomes, high pre-treatment EBV DNA levels was also associated with increased risk for disease progression, relapse, recurrence, and distant metastasis. Leung et al. [31] did not find an association between pre-treatment EBV DNA levels and overall survival (P= 0.2135); however, they also evaluated the association of EBV DNA levels with survival outcomes mid-way through treatment and found at this time point high levels of EBV DNA were associated with poor overall survival (P = 0.0077). Both pre-treatment and mid-treatment high EBV DNA levels were not associated with locoregional failure (P values ≥ 0.1378). The differences among Leung's, ours and other studies are not clear and may include differences in study design and assay conditions. Wang et al. [38] also found that the overall two-year survival rate was similar between patients with high pre-treatment EBV DNA (>5000 copies/mL) and low pre-treatment EBV DNA (≤5000 copies/mL); however, interpretation of the results of the Wang et al. study is confounded by the fact that it included only 34 patients.
One point that should be emphasized is that the relationship between EBV DNA load and overall survival is extremely robust. The majority of studies identified a negative impact of EBV DNA load, even though they differed in study design and assay cut-off values. Moreover, methods to quantitate DNA have evolved over the period of the review (15 years) and institutional protocols are not standardized [42, 43] . Use of real-time PCR to measure EBV DNA was first reported in 1999 [16, 44] , and since then, the availability and diversity of reagents and protocols have expanded considerably [45] . Not unexpectedly, several studies have documented substantial variability in quantitative assays [46] [47] [48] . The World Health Organization (WHO) introduced an EBV DNA standard in 2011 [49] , providing an opportunity for institutions to reduce the inter-institutional variability of their data. None of the studies included in this review used the WHO standard, indicating a greater need for harmonization in future studies. This crucial optimization will strengthen meta-analyses such as this one and allow more in-depth study of the effects of EBV burden on additional outcomes beyond mortality.
Our findings are similar to a recent meta-analysis by Zhang et al. [25] , where the objective was to assess the potential of plasma EBV DNA assays to predict clinical outcomes in patients with NPC [25] . Specifically, their meta-analysis evaluated the correlation between pre-treatment, mid-treatment and post-treatment EBV DNA and half-life value of plasma EBV DNA clearance rate (t 1/2 ) with clinical outcomes. Their meta-analysis included 14 studies with a total of 7836 patients. They found that high levels of pre-treatment, mid-treatment and post-treatment EBV DNA and slow EBV DNA clearance were all significantly associated with poorer overall survival (HRs ranged from 2.81-3.58 across endpoints). They also found that high levels of pre-treatment, mid-treatment and post-treatment EBV DNA were associated with a higher risk of disease progression, distant metastasis and increased locoregional failure. We did not evaluate locoregional failure survival in our study. Furthermore, we did not analyze the association of mid-treatment and post-treatment EBV DNA levels with survival outcomes because the primary objective of this study was to assess the pre-treatment DNA level. The use of pre-treatment EBV DNA levels can not only predict patient prognosis but also support diagnosis and treatment decisions While our meta-analysis was not focused on comparing detection rates for different clinical stages of NPC, it is an important issue that must be considered by institutions that currently use or in the future will use qPCR of EBV DNA to screen patients for NPC. In a recent paper published, Yip et al. discussed the limitations of EBV qPCR to detect stage I NPC [24] . Recent findings indicate that the sensitivity for detection of stage I NPC is substantially lower than that of stages II, III, and IV (50%-86% versus 94%-95%, 91%-100% and 94%-98%, respectively); however, these statistics may not influence clinicians' research efforts, as we identified only one trial that reported detection rates for patients with stage I disease [33] . The lack of data on use of EBV testing to detect stage I NPC may be expected, given that the majority of patients with NPC present at later stages [2] ; regardless, improving detection of early stage NPC would most likely lead to improved survival, and this should be a goal of future randomized trials.
There are several limitations to our meta-analysis. First, we did not perform subgroup analysis due to the cut-off values for copies of EBV DNA used varied across studies. Second, we did not have individual patient data but only aggregate data. The use and analysis of individual patient data, particularly with NPC which shows diverse disease outcomes even in patients with similar staged tumors, may give important insight into what patient characteristics influence the prognostic characteristics of pre-treatment EBV DNA levels in NPC. Third, of the included studies were randomized controlled studies raising the possibility that findings were influenced by selection and/or treatment allocation bias. Lastly, low enrollment of patients with WHO Type I tumors, coupled with incomplete reporting by the included studies, precluded a subgroup analysis of the prognosis of patients with each type of WHO tumor. Large studies should be conducted in low-incidence regions such as the United States and Japan, as these are known to have a higher proportion of patients with WHO type I NPC [24] .
In conclusion, our meta-analysis supports prior work that indicates pre-treatment plasma EBV DNA levels are highly prognostic of long-term survival and distant metastasis in patients with NPC. None of the included studies were randomized controlled trials and many had small patient populations, indicating the need for well-designed clinical trials to further test the use of EBV DNA in diagnosing and treating NPC.
